Titre Étude Pilote de Phase II Sur l'Effet du méthylphénidate Sur la Fonction Cognitive Des Patientes en rémission d'un Cancer du Sein
Protocole ID CogMet
ClinicalTrials.gov ID NCT02970500
Type(s) de cancer Sein
Phase Phase II
Type étude Support
Médicament Méthylphénidate
Institution CISSS DE CHAUDIERE-APPALACHES
   HOTEL-DIEU DE LEVIS
      143 rue Wolfe, Lévis, QC, G6V 3Z1
Ville Beauceville
Investigateur(trice) principal(e) Dre Anne Dagnault
Coordonnateur(trice) Pierre Bédard
 418-835-7121
Statut Actif en recrutement
Critètes d'éligibilité
  • Breast cancer stade I, II or III
  • had received chemotherapy and/or radiotherapy
  • being in remission of her breast cancer
  • complaining of cognitive impairment
Critètes d'exclusion
  • Current or recent use of psychostimulant drugs
  • Women receiving drugs like:
  • Anticoagulants 
  • Antidepressants
  • Drugs (cocaine)
  • Erythropoietin
  • Drugs acting on the cerebral dopaminergic system, including drugs that inhibit monoamine oxidase
  • Currently taking John's wort, natural medicines for depression or supplements for fatigue.
  • Conditions that may increase the risk of cognitive impairment or toxicity of methylphenidate such as :
  • Pregnancy and breastfeeding
  • Migraine, headache
  • Bipolar status 
  • Cerebral tumor or any brain injury
  • Metastatic cancer
  • Alcohol addiction
  • Drug
  • Active Major depression
  • Parkinson disease
  • Dementia 
  • Epilepsia,
  • Glaucoma 
  • Cardiovascular diseases
  • Auto-immunes and chronic inflammatory disease
  • Narcolepsia 
  • Pheochromocytome
  • Thyrotoxicosis
  • Motor tic, Gilles de la Tourette syndrome 
  • Anxiety